Chemotherapy of Fungal Diseases

  • John F. Ryley

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 96)

Table of contents

  1. Front Matter
    Pages I-XXV
  2. Drug Discovery

    1. John F. Ryley
      Pages 1-2
    2. F. Thomas Boyle
      Pages 3-30
    3. David Kerridge, Hugo Vanden Bossche
      Pages 31-76
    4. Manuel Debono, Robert S. Gordee
      Pages 77-109
    5. Robert F. Wilson, John F. Ryley
      Pages 111-128
    6. John F. Ryley
      Pages 129-147
  3. Drug Development

    1. John F. Ryley
      Pages 149-151
    2. Annemarie Polak
      Pages 153-182
    3. Michael H. Tarbit
      Pages 183-204
    4. Michael H. Tarbit, William R. Robertson, Ann Lambert
      Pages 205-229
    5. Oliver P. Flint, F. Thomas Boyle
      Pages 231-249
    6. Heinz Hänel, Wolfgang Ritter
      Pages 251-278
    7. Sarah C. Eardley
      Pages 279-311
    8. Thomas C. Jones, John J. Stern
      Pages 313-331
  4. Clinical Usage

    1. John F. Ryley
      Pages 333-334
    2. Marguerite M. Roberts
      Pages 335-363
    3. Thomas J. Walsh, Philip A. Pizzo
      Pages 399-419
    4. Bertrand Dupont
      Pages 421-437
    5. Donald Armstrong, Heinz J. Schmitt
      Pages 439-454
    6. Thomas C. Jones, Violette V. Villars
      Pages 483-503
    7. Annemarie Polak, Michel Zaug
      Pages 505-521
  5. Where Next?

    1. John F. Ryley
      Pages 523-524
    2. John F. Ryley, Robert S. Gordee, David Loebenberg
      Pages 525-550
  6. Back Matter
    Pages 551-558

About this book


Fungal diseases have been with us from antiquity; interest in the chemo­ therapy of fungal disease has exploded in the past decade. To plan and pro­ duce a book on the topic of antifungal chemotherapy has come as a personal challenge - and something of an eye-opener - towards the end of my re­ search career. A landmark publication which still merits reading is Antifungal Chemotherapy (John Wiley & Sons, Chichester, UK), edited by David Speller, which appeared in 1980. However, the fact that ketoconazole, the first of the modern, orally active, wide-spectrum antifungals, attracted no more than two sentences in it indicates just how far we have come in the 1980s. A steady stream of original papers and a number of conference proceedings have chronicled this progress in drug research; outstanding among the latter are the proceedings of an international telesymposium, entitled Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents, edited by Robert Fromtling (J.R. Prous, Barcelona, 1987) and volume 544 of the Annals of the New York Academy of Sciences, entitled Antifungal Drugs, edited by Vassil St. Georgiev, and containing papers and posters presented at a most enjoyable 3-day conference held at Garden City, New York, in the autumn of 1987.


Chemotherapeutikum Mykose Pilzkrankheit chemotherapy drug drug discovery screening

Editors and affiliations

  • John F. Ryley
    • 1
  1. 1.ICI PharmaceuticalsMacclesfield, CheshireEngland

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1990
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-75460-9
  • Online ISBN 978-3-642-75458-6
  • Series Print ISSN 0171-2004
  • Series Online ISSN 1865-0325
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods